ServicenavigationHauptnavigationTrailKarteikarten


Forschungsstelle
EU FRP
Projektnummer
99.0757
Projekttitel
CANCER VACCINE: Development of a cancer vaccine combining DNA and specific glycoprotein/glycopeptide formulation of a tumour antigen
Projekttitel Englisch
CANCER VACCINE: Development of a cancer vaccine combining DNA and specific glycoprotein/glycopeptide formulation of a tumour antigen

Texte zu diesem Projekt

 DeutschFranzösischItalienischEnglisch
Schlüsselwörter
-
-
-
Anzeigen
Alternative Projektnummern
-
-
-
Anzeigen
Forschungsprogramme
-
-
-
Anzeigen
Kurzbeschreibung
-
-
-
Anzeigen
Partner und Internationale Organisationen
-
-
-
Anzeigen
Abstract
-
-
-
Anzeigen
Datenbankreferenzen
-
-
-
Anzeigen

Erfasste Texte


KategorieText
Schlüsselwörter
(Englisch)
Biotechnology; Environmental Protection; Innovation; Technology Transfer; Life Sciences; Medicine; Health; Waste Management; Cancer vaccine; MUC1; DNA vaccination; glycopeptide/glycoprotein
Alternative Projektnummern
(Englisch)
EU project number: QLK3-1999-00217
Forschungsprogramme
(Englisch)
EU-programme: 5. Frame Research Programme - 1.1.3 The 'cell factory'
Kurzbeschreibung
(Englisch)
See abstract
Partner und Internationale Organisationen
(Englisch)
Coordinator: Imperial Cancer Research Fund, London (UK)
Abstract
(Englisch)
This innovative project will develop diagnostic kits using synthetic peptide Ags to detect Abs to post-translational proteins also preceding disorder symptoms not yet identified (via MOG model protein). Characterisation of native glycosylation will contribute to discover influence in Ab recognition. Molecular modelling will de- sign the best synthetic Ags for T- and B-cell response in animal models and patients affected by autoimmune diseases of nervous system (i.e., MS). These Ags will be used in a kit detecting anti-MOG Abs. A vital contribution to social objectives and to improvement of quality of life comes from a correlation study of Ab titre vs MRI. Validation/ exploitation of a very cheap kit (compared to current costs) will be done in Clinical Units involving patients (final users). A strategic impact surrogate marker for the follow-up of disease activity will be developed only thanks to critical mass of balanced multidisciplinary competence and to dissemination of the results.
Datenbankreferenzen
(Englisch)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 99.0757